Toboroz
Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Subjects With Metastatic Colorectal Cancer With KRAS p.G12C Mutation (CodeBreaK 301)
2022-502352-31-00· 3. fázis· Amgen Inc.· Forrás
Toboroz
Cannabidiol in refractory childhood epilepsy, a personalized high-quality approach
2023-507843-12-01· 3. fázis· Universitair Medisch Centrum Utrecht· Forrás
Toboroz
Atrial Fibrillation Ablation Versus Atrioventricular Nodal Ablation with Conduction System Pacing in Heart Failure
NCT06207383· University Hospital, Geneva· Forrás
Contact: Kevin Vernooy
Toboroz
Neoadjuvant Triple Therapy for (Borderline) Resectable Pancreatic Cancer (PREOPANC-5)
NCT06384560· 1/2. fázis· Amsterdam UMC, location VUmc· Forrás
Fut, nem toboroz
Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab
NCT06211036· 3. fázis· Amgen· Forrás
Toboroz
FeAsiBility of a Treatment Free Interval in Newly Diagnosed MM Patients Treated With Daratumumab-lenalidomide-dexamethasone (HOVON174MM)
NCT06187441· 3. fázis· Stichting Hemato-Oncologie voor Volwassenen Nederland· Forrás
Toboroz
Metamizole as pain treatment in patients with chronic pancreatitis, a multicenter, randomized, double-blind, placebo-controlled, superiority trial
2023-504143-14-00· 4. fázis· Stichting Radboud University Medical Center· Forrás
Toboroz
A multi-center, open-label, phase 2 study of Elranatamab in patients with high-risk smoldering multiple myeloma
2023-505775-70-00· 2. fázis· European Myeloma Network B.V.· Forrás
Toboroz
Improving Osimertinib Exposure and Cost-effectiveness Using Pharmacokinetic Boosting With Cobicistat
NCT05748093· 4. fázis· Maastricht University Medical Center· Forrás
Toboroz
TREASURE trial
2022-503135-33-00· 4. fázis· University Hospital Maastricht· Forrás
Fut, nem toboroz
Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment
NCT06151574· 3. fázis· Boehringer Ingelheim· Forrás
Toboroz
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
NCT06152575· 3. fázis· Pfizer· Forrás
Toboroz
Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer
NCT05950945· 3. fázis· Daiichi Sankyo· Forrás
Toboroz
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
NCT05920356· 3. fázis· Amgen· Forrás
Fut, nem toboroz
Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2
NCT05911295· 3. fázis· Seagen, a wholly owned subsidiary of Pfizer· Forrás
Toboroz
Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
NCT05855200· 3. fázis· GlaxoSmithKline· Forrás
Fut, nem toboroz
Tislelizumab, Gemcitabine and Cisplatin for R/R Hodgkin Lymphoma Followed by Tislelizumab Consolidation in Patients in Metabolic Complete Remission
NCT05502250· 2. fázis· Stichting Hemato-Oncologie voor Volwassenen Nederland· Forrás
Fut, nem toboroz
A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
NCT05578976· 3. fázis· Genmab· Forrás
Fut, nem toboroz
The RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe CKD
NCT05374291· 3. fázis· University Medical Center Groningen· Forrás
Fut, nem toboroz
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
NCT05283720· 2. fázis· Genmab· Forrás
Toboroz
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
NCT04928846· 3. fázis· AbbVie· Forrás
Toboroz
Comparison of Standard Dose Alectinib to Alectinib in Adjusted Dose Based on Alectinib Bloodlevels
NCT05525338· 4. fázis· University Medical Center Groningen· Forrás
Fut, nem toboroz
A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)
NCT05239728· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Fut, nem toboroz
Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)
NCT05173987· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Toboroz
Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features
NCT05255653· 3. fázis· Leiden University Medical Center· Forrás
Fut, nem toboroz
A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma
NCT05050097· 1. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)
NCT04895358· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Fut, nem toboroz
An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
NCT04720157· 3. fázis· Novartis Pharmaceuticals· Forrás
Toboroz
REtreatment With VEnetoclax and Acalabrutinib After Venetoclax Limited Duration (REVEAL)
NCT04523428· 2. fázis· Stichting Hemato-Oncologie voor Volwassenen Nederland· Forrás
Fut, nem toboroz
Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome
NCT04623541· 1/2. fázis· Genmab· Forrás
Toboroz
Induction Chemotherapy for Locally Recurrent Rectal Cancer
NCT04389086· 3. fázis· Catharina Ziekenhuis Eindhoven· Forrás
Toboroz
FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery
NCT04016389· 2. fázis· University Health Network, Toronto· Forrás
Fut, nem toboroz
Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
NCT03772028· 3. fázis· The Netherlands Cancer Institute· Forrás
Fut, nem toboroz
A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy
NCT04027309· 3. fázis· Stichting Hemato-Oncologie voor Volwassenen Nederland· Forrás
Fut, nem toboroz
Tolerability and Efficacy of Midostaurin to 10-day Decitabine in Unfit Adult AML and High Risk MDS Patients
NCT04097470· 2. fázis· Stichting Hemato-Oncologie voor Volwassenen Nederland· Forrás
Fut, nem toboroz
Immunotherapy, Chemotherapy, Radiotherapy and Surgery for Synchronous Oligo-metastatic NSCLC
NCT03965468· 2. fázis· ETOP IBCSG Partners Foundation· Forrás
Fut, nem toboroz
A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy
NCT03839771· 3. fázis· Stichting Hemato-Oncologie voor Volwassenen Nederland· Forrás
Fut, nem toboroz
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)
NCT03711032· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Fut, nem toboroz
The Feasibility and Clinical Efficacy of Atezolizumab Consolidation Treatment in High Risk (IPI > 2) DLBCL
NCT03463057· 2. fázis· Stichting Hemato-Oncologie voor Volwassenen Nederland· Forrás
Fut, nem toboroz
HOVON 152 DLBCL. A phase II study evaluating the effect of DA-EPOCH-R induction followed by nivolumab consolidation in patients with newly diagnosed high grade B cell lymphoma (HGBL) with MYC and BCL2 and/or BCL6 rearrangements
NCT03620578· 2. fázis· Stichting Hemato-Oncologie voor Volwassenen Nederland (Hovon)· Forrás
Fut, nem toboroz
Nivolumab in Patients With Type B3 Thymoma and Thymic Carcinoma (NIVOTHYM)
NCT03134118· 2. fázis· European Organisation for Research and Treatment of Cancer - EORTC· Forrás
Toboroz
Phase I-II Study in CD30 Positive Diffuse Large B-cell Lymphoma Patients Refractory to First Line Chemotherapy or in First Relapse
NCT03356054· 1/2. fázis· Stichting Hemato-Oncologie voor Volwassenen Nederland· Forrás
Fut, nem toboroz
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
NCT02960022· 2. fázis· Astellas Pharma Global Development, Inc.· Forrás
Toboroz
DRUP trial
NCT02925234· 2. fázis· Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting· Forrás